PALOMA-1 Trial Finds Palbociclib/Letrozole Doubles Progression-Free Survival in Metastatic Breast CancerAlice Goodman
At the plenary session of the AACR, the phase II PALOMA-1 trial results were presented in which the cyclin-dependent kinase 4/6 inhibitor, palbociclib, was combined with letrozole and compared with letrozole alone in the front-line setting for the treatment of women with metastatic disease. ...